Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| In concluding this earnings call, I would like to know that we at Protalix are proud of our accomplishments |
| We believe PRX-115 is potentially a good candidate to target this market |
| A worldclass team, a strong balance sheet supporting our strategic plans and a strategic vision to creating a long-term value for our stockholders |
| Eliot's reputation in management and leadership in the life science field speaks for itself, and he has a record of success in the United States, the European Union and Asia |
| We are also pleased that Elfabrio has been granted additional regulatory approvals outside the EU, like in Great Britain and Switzerland, and we look forward to continued global growth of Elfabrio |
| I'm grateful for our entire Protalix team, their enduring commitment and resolve at this time as we develop a portfolio for patients with unmet medical needs is noteworthy |
| We have a proven platform technology with two approved therapeutics driving a rich and sustainable pipeline of assets |
| Before turning the call to over to Eyal, I want to know that our strong balance sheet provides us with sufficient cash runway to maintain current operations without the need for near-term capital infusion |
| We are grateful to Zeev for his dedication and leadership since the founding of Protalix many, many years ago, and we look forward to working with Eliot and leveraging his expertise as we enter this exciting phase of development for this company |
| Since we are not doing anything in the equity capital markets, so obviously, I guess gradually, slowly, but surely when revenues are going to start to ramp up, the big boys are going to join the party and we're going to see that we have a stable streamline of revenues and we are accumulating cash |
| We recorded revenues from selling goods of $10.2 million during the three months ended September 30th, 2023, an increase of $1.4 million or 16% compared to revenues of $8.8 million for the three months ended September 30th, 2022 |
| Good day to you |
| We appreciate all those who have been reached out to Protalix to express their concern and support and we thank you for joining us today |
| The increase resulted primarily from an increase of $3 million in sales to Chiesi, following the approval by the FDA and the EMA, as Dror mentioned, of Elfabrio, and of $0.6 million in sales to Brazil, partially offset by $2.2 million decrease in sales to Pfizer |
| I'm still recovering from sore throat |
| Let me now turn to our accomplishments this quarter |
| On the corporate side, we welcome Dr |
| So thanks for taking our questions |
| Yes, I think it's very, very, very fluctuating |
| Thank you all |
| Dror Bashan So thank you everybody for your participation |
| And thank you everyone for joining today's call |
| I will now review our recent progress and accomplishments |
| Thank you for that |
| As we said, the company at this point is self-sustained |
| Statement |
|---|
| I see that the revenue dropped from $15 million in second quarter to $10 million in the third quarter |
| Recorded revenues from license and R&D services of $0.2 million for the three months ended September 30th, 2023, a decrease of $5.2 million, or 96%, compared to revenues of $5.4 million for the three months ended September 30, 2022 |
| We at Protalix are horrified by the devastating events that have been taking place in recent weeks |
| It is an extremely challenging time and we are heartbroken for the victims, families, friends and loved ones, many of us being personally impacted |
| So we don't feel comfortable at this point sharing the forecasts for the next couple quarters |
| Safety for sure, but more than that |
| So I think at this point it's going to be irresponsible to share forecasts for the short term |
| Before we start taking questions, I would like to note that we are praying for our friends and family during this challenging time |
| Cost of goods sold was $4.9 million for the three months ended September 30th, 2023, a decrease of $2.2 million, or 31%, from cost of goods sold of $7.1 million for the three months ended September 30th, 2022 |
Please consider a small donation if you think this website provides you with relevant information